Skip to search formSkip to main contentSkip to account menu

Anti-Epidermal Growth Factor-like Domain 7 Monoclonal Antibody MEGF0444A

Known as: MEGF 0444A, MEGF0444A 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Parsatuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Phase Ib study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab…
e13000 Background: Epidermal growth factor-like domain 7 (EGFL7), is a vascular-restricted, tumor selective, extracellular matrix… 
2011
2011
Population pharmacokinetic (PK) analysis supports fixed dosing for the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors.
2586 Background: Monoclonal antibody therapeutics in oncology are most frequently dosed using body weight (BW)-based dosing… 
2011
2011
1201 ORAL Early Studies of the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Anti-tumour Activity of the Humanized Monoclonal Antibody (huMAb) Anti-EGFL7 (MEGF0444A) Alone and in…
2011
2011
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a pharmacodynamic (PD) biomarker in phase I trials of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A).
2539 Background: DCE-MRI allows for the functional analysis of tumor microcirculation and composition, and has been used to… 
2011
2011
A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A…
2614 Background: Epidermal growth factor-like domain 7 (EGFL7), is a vascular-restricted, tumor selective, extracellular matrix… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)